GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shanghai Haohai Biological Technology Co 688366.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

29.47

-1.77%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥2.47bn

FY2016FY2025

Net income

CN¥251.0m

FY2016FY2025

Free cash flow

CN¥304.0m

FY2016FY2025

Shareholders' equity

CN¥5.42bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥2.47bnCN¥2.68bnCN¥2.63bnCN¥2.10bnCN¥1.75bnCN¥1.32bnCN¥1.60bnCN¥1.55bnCN¥1.34bnCN¥851.2m
Gross profitCN¥1.71bnCN¥1.84bnCN¥1.85bnCN¥1.45bnCN¥1.26bnCN¥990.4mCN¥1.23bnCN¥1.21bnCN¥1.06bnCN¥709.6m
Research and developmentCN¥197.8mCN¥260.8mCN¥241.6mCN¥206.3mCN¥185.3mCN¥138.3mCN¥127.4mCN¥105.5mCN¥82.9mCN¥47.7m
Operating incomeCN¥220.5mCN¥347.9mCN¥368.3mCN¥155.8mCN¥176.0mCN¥79.7mCN¥291.0mCN¥368.5mCN¥365.7mCN¥284.0m
Net incomeCN¥251.0mCN¥420.4mCN¥416.1mCN¥180.5mCN¥352.2mCN¥230.1mCN¥370.8mCN¥414.5mCN¥372.4mCN¥305.1m
Diluted earnings per share1.081.811.780.531.030.681.101.321.190.97

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥6.72bnCN¥7.12bnCN¥7.11bnCN¥6.89bnCN¥6.95bnCN¥6.30bnCN¥6.15bnCN¥4.44bnCN¥4.08bnCN¥3.69bn
Cash and short-term investmentsCN¥2.52bnCN¥2.72bnCN¥2.75bnCN¥2.54bnCN¥2.91bnCN¥3.11bnCN¥3.22bnCN¥1.44bnCN¥1.80bnCN¥2.01bn
Total liabilitiesCN¥1.12bnCN¥1.20bnCN¥1.09bnCN¥990.0mCN¥890.1mCN¥564.5mCN¥498.5mCN¥600.9mCN¥708.6mCN¥707.6m
DebtCN¥398.5mCN¥448.4mCN¥407.9mCN¥118.3mCN¥105.5mCN¥108.1mCN¥49.7mCN¥36.7mCN¥37.5mCN¥26.7m
Shareholders' equityCN¥5.42bnCN¥5.58bnCN¥5.65bnCN¥5.51bnCN¥5.71bnCN¥5.49bnCN¥5.45bnCN¥3.61bnCN¥3.20bnCN¥2.90bn
Shares outstanding232m232m234m338m344m338m338m314m314m314m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥491.0mCN¥648.6mCN¥634.5mCN¥231.3mCN¥342.3mCN¥262.1mCN¥348.9mCN¥391.3mCN¥343.1mCN¥254.5m
Capital spending−CN¥186.9m−CN¥365.5m−CN¥267.2m−CN¥317.1m−CN¥272.1m−CN¥195.9m−CN¥399.3m−CN¥151.9m−CN¥134.7m−CN¥75.7m
Free cash flowCN¥304.0mCN¥283.1mCN¥367.2m−CN¥85.9mCN¥70.2mCN¥66.2m−CN¥50.4mCN¥239.4mCN¥208.3mCN¥178.8m
Dividends paid−CN¥228.7m−CN¥259.9m−CN¥68.5m−CN¥121.9m−CN¥87.9m−CN¥124.0m−CN¥80.0m−CN¥80.0m−CN¥85.8m−CN¥58.6m

Latest quarters

By quarter end

Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024
RevenueCN¥573.9mCN¥594.7mCN¥685.9mCN¥618.5mCN¥604.9mCN¥670.4mCN¥758.4mCN¥646.0m
Gross profitCN¥1.14bnCN¥439.7mCN¥467.0mCN¥430.0mCN¥375.5mCN¥488.1mCN¥525.8mCN¥447.1m
Operating income−CN¥105.4mCN¥89.6mCN¥132.5mCN¥103.8m−CN¥387.5mCN¥124.7mCN¥148.4mCN¥114.4m
Net income−CN¥53.6mCN¥93.6mCN¥120.8mCN¥90.3mCN¥79.6mCN¥105.6mCN¥137.7mCN¥97.5m
Diluted earnings per share-0.230.400.520.390.340.460.590.42
Cash from operations—CN¥109.0mCN¥217.0mCN¥91.0mCN¥224.0mCN¥109.0mCN¥252.0mCN¥75.0m
Capital spending—−CN¥47.0m−CN¥28.0m−CN¥59.0m−CN¥83.0m−CN¥57.0m−CN¥68.0m−CN¥153.0m
Free cash flow—CN¥62.0mCN¥189.0mCN¥32.0mCN¥141.0mCN¥52.0mCN¥184.0m−CN¥78.0m
Total assetsCN¥6.72bnCN¥7.12bnCN¥7.19bnCN¥7.13bnCN¥7.12bnCN¥7.25bnCN¥7.24bnCN¥7.19bn
Cash and short-term investments—CN¥2.60bnCN¥2.66bnCN¥2.66bnCN¥2.73bnCN¥2.69bnCN¥2.74bnCN¥2.73bn
DebtCN¥33.1mCN¥299.6mCN¥411.2mCN¥329.6mCN¥310.2mCN¥285.5mCN¥398.4mCN¥390.2m
Shareholders' equityCN¥5.42bnCN¥5.62bnCN¥5.61bnCN¥5.67bnCN¥5.58bnCN¥5.67bnCN¥5.69bnCN¥5.76bn

Financial ratios

Data as of 7 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin69.2%68.5%70.1%68.8%72.0%74.8%
Operating margin9.7%18.1%19.6%11.6%22.1%19.8%
Net margin10.1%15.7%15.8%8.6%20.1%17.4%
Return on equity4.6%7.5%7.4%3.3%6.2%4.2%
Return on assets3.7%5.9%5.9%2.6%5.1%3.7%
Free cash flow yield9.6%14.4%12.7%5.3%5.9%4.5%
Revenue growth-7.7%1.7%25.3%20.2%32.1%-17.0%
Earnings growth-40.3%1.0%130.6%-48.8%53.1%-37.9%
Current ratio3.79x4.22x5.24x6.91x7.62x8.78x
Debt to equity0.07x0.07x0.07x0.01x0.02x0.02x
Equity ratio80.7%78.3%79.5%80.0%82.2%87.2%
Interest coverage12.69x26.81x70.67x32.00x78.10x53.40x
R&D as a share of sales8.0%9.7%9.2%9.8%10.6%10.4%
Buybacks as a share of market value-0.0%0.8%30.8%1.6%-1.6%-0.1%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue5.5%13.3%14.1%
Operating income12.3%22.6%-0.1%
Net income11.6%1.8%-0.9%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin68.9%69.2%70.1%73.1%
Operating margin11.0%11.0%10.4%15.2%
Net margin13.0%12.8%14.3%18.9%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Price to earnings40.633.443.5130.587.794.658.5
Price to sales4.15.26.911.217.616.413.6

Dividends and splits

Per share, in the currency the company pays

Paid for 6 years. Last went ex-dividend on 17 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Paid in the year0.601.001.1140.2860.500.3570.50
  • 7-for-5 split · 20 Jun 2024

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.